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Background: F-fluorodeoxyglucose positron emission tomography (FDG-PET) is increasingly used to investigate for
malignancy in the evaluation of pulmonary nodules, yet both active tuberculosis (TB) and malignancy have high
uptake of FDG. Definitive diagnosis of TB can be further hindered in patients without growth of the organism from
sputum.
Case presentations: We describe a series of four representative cases of TB in varying disease state originally
imaged by FDG-PET during evaluation for malignancy. Decisions regarding treatment for active TB in the presence
of negative cultures and the evolving understanding of the spectrum of the TB disease state are discussed.
Conclusions: FDG-PET may possess a role in the diagnosis of active TB infection in settings where conventional
microbiological methods are unavaiable and holds particular promise for monitoring response to therapy in cases
of unsettled treatment duration such as multidrug-resistant TB or in extrapulmonary TB.
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Diagnosis of tuberculosis (TB) can be challenging in pa-
tients without growth of Mycobacterium tuberculosis in
sputum or in patients with atypical extrapulmonary
presentations. Tuberculin skin tests (TST) or serum
interferon-gamma release assays can determine TB ex-
posure but cannot distinguish between latent and active
disease. Chest x-rays are performed as part of traditional
evaluation for active disease, but in the modern era
many individuals undergo chest computed tomography
(CT) scans which reveal significantly more abnormal-
ities. A common scenario is the patient with a pulmon-
ary nodule diagnosed by CT, who is then referred
for 18F-fluorodeoxyglucose positron emission tomog-
raphy (FDG-PET), most commonly combined FDG-
PET/CT, in order to evaluate for malignancy [1]. Yet,
when imaged by FDG-PET, both malignant lesions and
those with active M. tuberculosis infection may have
high uptake of FDG [2]. We describe four challenging* Correspondence: skh8r@virginia.edu
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reproduction in any medium, provided the orbut representative cases evaluated for active pulmon-
ary TB based on FDG-PET/CT performed for the
work-up of malignancy and explore the potential niche
for FDG-PET in TB management. Age, gender, country
of origin and other identifiers have been removed for




An elderly patient was born in a country non-endemic
for TB, but had been exposed to active TB as a teenager
and despite a positive TST, had never received latent TB
infection treatment. The patient presented with 1–2 -
months of fatigue and cough. Radiograph revealed right
and left upper lobe nodules with hilar and mediastinal
lymphadenopathy. FDG-PET/CT scan found the left
lung nodule with maximum SUV of 2.5 and a more in-
tensely FDG-avid adjacent lymph node with maximum
SUV of 5.1 (Figure 1A). Smear microscopy for acid-fast
bacilli and mycobacterial culture of the sputum were
negative. Ultimately a videoscopic wedge resection of the
left lung found multiple granulomas and a mediastinalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 Representative FDG-PET/CT images. A. Case 1: axial CT (left) and fused FDG-PET/CT, with abnormal FDG uptake in the mediastinal
lymph nodes. B. Case 2: fused FDG-PET/CT highlighting abnormal uptake in the right upper lobe nodule and more intense uptake in mediastinal
lymph nodes. C. Case 3: axial CT (left) and fused FDG-PET/CT (right) with abnormal uptake in the right upper lobe nodule.
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The patient was started on four-drug anti-tuberculosis
therapy, but was intolerant of pyrazinamide, thus ulti-
mately completed a total of 9 months of treatment with
complete symptom and radiographic resolution. There
was no evidence of disease recurrence at 1 year of
follow-up after treatment completion.
Case 2
An elderly patient emigrated from a TB endemic country
five years prior and had known TB contacts, was found
to have a poorly differentiated squamous cell carcinoma
of the cervix. The patient endorsed fatigue, a non-
productive cough and 10 pound weight loss in the ante-
cedent 4 months. Pre-chemotherapy work-up included a
positive TST. FDG-PET/CT was performed for cancer
staging and demonstrated the cervix mass as well as an
FDG avid, peripheral nodular lesion in the right upper
lobe of the lung, measuring approximately 1.6 × 1.4 cm
and prominent hypermetabolic mediastinal lymph nodes
adjacent to the right upper lobe bronchus, the largest
with a maximum standardized uptake value (SUV) of 11
(Figure 1B). Three sputum samples were negative foracid fast bacilli by smear microscopy. Given that the pul-
monary imaging was atypical for metastatic cervical can-
cer and favored to represent TB infection, and that
active TB could not be ruled out which carried signifi-
cant patient care and infection control implications
while hospitalized for urgent cancer therapy, the patient
was started on 4-drug treatment for active pulmonary
TB. After two months of therapy, excessive nausea pre-
cluded continuation of her TB treatment, all cultures
remained negative, and thus no further therapy was im-
mediately pursued. To date, the patient has not had re-
turn of TB symptoms, now greater than 6 months after
conclusion of therapy.
Case 3
An elderly patient from a non-endemic TB country was
incidentally found to have a right upper lobe lung mass
detected on a CT scan of the head/neck performed for
evaluation of transient ischemic attacks. He was a life-
time non-smoker and had no symptoms of active TB.
However, the patient was treated for TB as a young adult
with 6 months of isoniazid and 4-aminobenzoic acid. To
further evaluate the lung mass FDG-PET/CT scan of the
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nodular lesion measuring 3.0 cm with a peak SUV of
5.75; no metabolically active perihilar or mediastinal
lymph nodes were seen (Figure 1C). While a videoscopic
wedge resection of the mass was negative for malig-
nancy, gross pathology revealed a central cavity abutting
the pleura. Histology found granulomatous inflammation
and immunohistochemical staining for M. tuberculosis
demonstrated rare intracellular rod forms. Bacterial, fun-
gal and mycobacterial cultures as well as M. tuberculosis
PCR of the tissue were negative. Given the histopa-
thology and FDG-PET findings, anti-tuberculosis treat-
ment was recommended but the patient refused and was
lost to follow-up.
Case 4
An elderly patient from a TB endemic country who had
been treated for active TB 50 years prior, presented with
fever and cough of one week’s duration following an
international flight from the patient’s country of origin.
Chest x-ray revealed biapical pleural thickening, bron-
chiectasis and a patchy right hilar consolidation. Expec-
torated sputum samples and bronchioalveolar lavage
were unremarkable and negative for acid fast bacilli. The
patient was planning on returning to the home country
by plane as soon as medically cleared. The patient also
had a history of multiple urological malignancies. In this
setting FDG-PET/CT was performed which confirmed
the biapical thickening and linear densities of the apices,
but was without any significant FDG uptake in the lungs
or adjacent lymph nodes. He was discharged without TB
treatment and all cultures finalized as negative.
Conclusions
FDG-PET/CT is an increasingly accessed technology for











Figure 2 Spectrum of tuberculosis infection with proposed relationsh
unknown percentage will clear infection entirely, while the vast majority de
all bacteria or leave a small population in a dormant non-replicating state.
held under immunological control (noted by the dotted line) [10, 11]. Yet a
increases (noted by the hashed line). Cases 1–4 are presumptively placed a
microbiological studies and 18 F-fluorodeoxyglucose positron emission tomprevalence [3] and therefore understanding the potential im-
pact for its use in TB diagnosis and management is import-
ant for clinicians ordering and interpreting FDG-PET/CT.
FDG uptake reflects cell glycolysis and is found in activated
macrophages and lymphocytes [4], both of which are pro-
minent in TB and other granulomatous inflammatory pro-
cesses, as well as in neoplastic cells. The rate of uptake is
reported as a standardized uptake value (SUV), the regional
radioactivity concentration divided by the total injected dose
and adjusted to the patient weight [5]. The maximum SUV
is elevated in active TB. For instance, in a study of 150 sub-
jects undergoing work-up for pulmonary nodules at a South
Korean hospital, 10 cases of active pulmonary TB were iden-
tified and 9 (90%) had nodules with a maximum SUV above
the threshold of 2.5 [6]. In a separate study of 25 subjects
with culture-confirmed pulmonary TB, the mean maximum
SUV was 4.96 ± 1.61 [7]. In addition, the maximum SUV de-
clines on treatment, as demonstrated by a series of 21 HIV
uninfected TB patients in whom the maximum SUV de-
creased by a median of 31% at one month of therapy [8].
Extrapulmonary sites of disease, particularly lymph nodes
[9], may have an even higher maximum SUV, as was
observed in Case 2. While quantitative assessment of SUV
cannot distinguish active tuberculosis from malignancy [10],
use of adjunctive tracers such as 11C-choline and 18F-
fluorothymidine may provide improved discrimination. In a
study of 97 patients with lung cancer, 14 with active pulmon-
ary TB and 5 with non-tuberculous mycobacteria, the SUV
of 11C-choline was low in active TB compared to lung can-
cer, and values of FDG and 11C-choline were both low in the
patients with non-tuberculous mycobacteria [5].
Studies in humans examining FDG-PET for distin-
guishing latent and active TB are limited, but in one report
of 25 patients, pulmonary TB disease activity was scored
based on histopathology, culture and response to anti-




progressive TB until treated
ing
Case 1
Lack of immune control
Case 2
hronic
ip to FDG-PET findings. Following exposure to M. tuberculosis an
velop latency (adapted from [10, 11]). Treatment of TB may eradicate
Populations with occasional replication termed “percolating” can be
s bacterial burden increases, the risk of progression to active infection
long the proposed spectrum based on clinical, histopathological and
ography (FDG-PET) avidity.
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minutes post-injection respectively) in patients with active
compared to inactive TB [11]. Therefore a pulmonary
nodule with high uptake on FDG-PET in a patient with
evidence of TB exposure by positive TST or interferon-
gamma release assay may tip the balance of treatment
toward active TB, particularly if resection with histopa-
thology and culture cannot be performed or if further
immunosuppressing chemotherapy is immediately planned,
as in Case 2.
Complicating the matter, however, is recent work in
non-human primates that suggests the TB disease state
may be more dynamic than previously believed [12,13].
Rather than simply latent or active, TB infection occu-
pies a more diverse spectrum (Figure 2). In certain indi-
viduals a robust acquired immune response with T-cell
priming may have eliminated infection completely while
in others a quiescent infection remains with some myco-
bacteria persisting in non-replicating form [13,14]. In a
small proportion of patients, the immune response has
kept active infection of replicating mycobacteria at the
sub-clinical level, while in other patients, active inflam-
mation, TB replication, and symptoms propagate
[13, 14]. Therefore, high uptake of FDG by PET may
represent ongoing active disease, as demonstrated by
Case 1, or simply the host immune system activity that
will ultimately prevail, such as could be argued for Case
3 (Figure 2). Given such emerging evidence from non-
human primates, we would not advocate for the imme-
diate adoption of FDG-PET/CT in treatment decisions
regarding TB latency. However the implications of FDG-
PET/CT findings must be considered in patients for
whom this modality was employed for another clinical
indication, as exemplified by Case 2, in whom low-grade
TB symptoms may have been masked by the concurrent
malignancy.
Perhaps the most promising role of FDG-PET/CT is
in the monitoring of therapeutic response in select cases
of extrapulmonary TB where sputum culture is unavail-
able, or in multidrug-resistant (MDR)-TB where second-
line drugs are less efficacious and definitive treatment
duration is not known [15]. Extrapulmonary tuber-
culoma may persist with little change for years if imaged
with conventional radiology [16]. Uncontrolled case
series have described the benefit of decreased FDG up-
take following treatment in extrapulmonary sites of dis-
ease. In a series of 30 patients with TB of the spine for
instance, the percent change in maximum SUV discrimi-
nated residual infection from successful treatment [17].
Another conceivable issue is that if imaged too early in
the course of treatment, a paradoxical increase in FDG
uptake may be observed due to immune reconstitution,
however, this has not been observed in animal models
[14]. The use of FDG-PET/CT has only begun to bereported for MDR-TB [18], but in a murine model of TB
treatment FDG uptake correlated with mycobacterial
burden in the lung and decreased proportional to the
degree of bactericidal activity of the drug regimen [19].
Furthermore, in a promising series of HIV co-infected
TB patients from South Africa, the number of lymph
node bastions was found predictive of response to drug-
susceptible TB treatment and a surrogate marker for
clinical MDR-TB [18]. Given that the cost of treating
MDR-TB may be 100 times more expensive than drug-
susceptible TB, the decision to extend or shorten treat-
ment, in some cases upward of 24 months, may defray
the cost of FDG-PET/CT in certain well-resourced
settings. Despite conceptual appeal for the use of FDG-
PET/CT in assessment of transmissibility or even relapse
following therapy, as was done in part for Case 4, further
data are required to support these applications.
In summary, FDG-PET/CT is an increasingly employed
modality and TB clinicians should become familiar with
its use. FDG-PET/CT may need to be interpreted in the
context of distinguishing latent versus active disease, and
it has the potential to become a tool in monitoring treat-
ment response in select cases of extrapulmonary TB or
multidrug-resistance.
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